Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 4/20 | 0.34 |
| ▸ | MAPT | P10636 | 4/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | PTGS2 | P35354 | 5/20 | 0.33 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.33 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.33 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.33 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.33 |
| ▸ | CFTR | P13569 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | LMNA | P02545 | 2/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | EDNRA | P25101 | 1/20 | 0.32 |
| ▸ | MAOB | P27338 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | USP2 | O75604 | 1/20 | 0.31 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.31 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12339077 | 0.86 | UGT1A1 (0.42) | GAAMAPTPTGS2MAPK13MAPK12 | |
| SCHEMBL1167898 | 0.85 | ALDH1A1 (0.42) | MAPTALDH1A1LMNAHPGDNPSR1 | |
| SCHEMBL12339074 | 0.84 | PTGS2 (0.32) | PTGS2RAB9A | |
| SCHEMBL10189274 | 0.81 | CFTR (0.36) | GAAMAPTTP53PTGS2CFTR | |
| SCHEMBL12339075 | 0.80 | PRKAB2 (0.33) | PTGS2 | |
| SCHEMBL12339076 | 0.78 | PTGS2 (0.32) | MAPTPTGS2MAPK13MAPK12MAPK11 | |
| SCHEMBL12339064 | 0.78 | CYP2A6 (0.40) | — | |
| SCHEMBL12339073 | 0.77 | NPC1 (0.32) | RAB9A | |
| SCHEMBL12339060 | 0.77 | ALDH1A1 (0.35) | MAPTALDH1A1LMNAHPGDNPSR1 | |
| SCHEMBL10189775 | 0.76 | MAPT (0.34) | GAAMAPTTP53PTGS2MAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9090603-B2 | Compounds for the treatment of proliferative disorders | SYNTA PHARMACEUTICALS CORPORATION (US) | 2015-07-28 | — | — | US | disclosed |
| US-20140045795-A1 | COMPOUNDS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | SYNTA PHARMACEUTICALS CORPORATION (US) | 2014-02-13 | — | — | US | disclosed |
| US-20120289483-A1 | COMPOUNDS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | SYNTA PHARMACEUTICALS CORPORATION (US) | 2012-11-15 | — | — | US | disclosed |
| US-8269017-B2 | Compounds for the treatment of proliferative disorders | SYNTA PHARMACEUTICALS CORPORATION (US) | 2012-09-18 | — | — | US | disclosed |
| US-20110059893-A1 | COMPOUNDS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | SYNTA PHARMACEUTICALS CORP. | 2011-03-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140045795-A1 | COMPOUNDS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | RB1, MKI67, MAPRE1 | GAA 597/4885MAPT 95/4885TP53 25/4885 |
| US-20120289483-A1 | COMPOUNDS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | RB1, MKI67, MAPRE1 | GAA 597/4885MAPT 95/4885TP53 25/4885 |
| US-20110059893-A1 | COMPOUNDS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | RB1, MKI67, MAPRE1 | GAA 597/4885MAPT 95/4885TP53 25/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.